Evidence of Multiyear Factor IX Expression by AAV-Mediated Gene Transfer to Skeletal Muscle in an Individual with Severe Hemophilia B

This publication has 16 references indexed in Scilit:

• Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
  Nature Medicine, 2006
• Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model
  Blood, 2005
• Factor IX variants improve gene therapy efficacy for hemophilia B
  Blood, 2005
• Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1
  Blood, 2004
• AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
  Blood, 2003
• Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
  Nature Genetics, 2000
• Haemophilia B: database of point mutations and short additions and deletions--eighth edition
  Nucleic Acids Research, 1998
• Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia
  Gene Therapy, 1998
• Haemophilia prophylaxis in young patients–a long‐term follow‐up
  Journal of Internal Medicine, 1997
• Identification of the endothelial cell binding site for factor IX.
  Proceedings of the National Academy of Sciences, 1996